Non-insulin and non-exercise related increase of glucose utilization in rats and mice.
The effects of high-energy phosphate contents in muscles on glucose tolerance and glucose uptake into tissues were studied in rats and mice. Enhanced glucose tolerance associated with depleted high-energy phosphates and elevated glycogen content in muscles and liver was observed in animals fed creatine analogue beta-guanidinopropionic acid (beta-GPA). Distribution of infused 2-[1-14C]deoxy-D-glucose in tissues especially in the soleus muscle, kidney, and brain was greater in mice fed beta-GPA than controls. The glucose uptake was decreased when the contents of ATP and glycogen were normalized following creatine supplementation. Plasma insulin in animals at rest was lower and its concentration after intraperitoneal glucose infusion tended to be less in animals fed beta-GPA than controls (p > 0.05), although the pattern of insulin response to glucose loading was similar to the control. The daily voluntary activity in beta-GPA fed mice was also less than controls. These results suggest that improved glucose tolerance is not related to elevated insulin concentration and/or decreased glycogen following exercise. Such improvement may be due to an increased mitochondrial energy metabolism caused by depletion of high-energy phosphates.
Ohira
Y
Y
Department of Physiology and Biomechanics, National Institute of Fitness and Sports, Kanoya, Japan.
Ishine
S
S
Tabata
I
I
Kurata
H
H
Wakatsuki
T
T
Sugawara
S
S
Yasui
W
W
Tanaka
H
H
Kuroda
Y
Y
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003847:Deoxyglucose / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D005951:Glucose Tolerance Test; D006003:Glycogen / Q000378:metabolism; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D010710:Phosphates / Q000378:metabolism; D010805:Physical Conditioning, Animal; D011422:Propionates / Q000008:administration & dosage / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution / Q000187:drug effects
D001786:Blood Glucose; D006146:Guanidines; D007328:Insulin; D010710:Phosphates; D011422:Propionates; D006003:Glycogen; D003847:Deoxyglucose; D005947:Glucose; C005775:guanidinopropionic acid